Korea Reimburses Gilead's Sovaldi, Harvoni To Aid Access
This article was originally published in PharmAsia News
Executive Summary
With China and Japan moving to cut prices of Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni, South Korea has decided to reimburse the products from May. Although not all HCV genotypes will be covered by national health insurance, the move will sharply ease local patients' cost burden amid an outbreak of infections last year.